-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 9 News On July 8, Shandong Dyne Marine Biopharmaceuticals and Shandong Liangfu Pharmaceuticals submitted applications for the imitation of tacrolimus ointment in four categories and were accepted
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
Figure 1: The latest product status
Source: CDE official website
Tacrolimus ointment is suitable for the treatment of patients with moderate to severe atopic dermatitis who are not immunocompromised due to potential danger and who are not suitable for traditional therapies or who do not respond adequately to or can not tolerate traditional therapies.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
Figure 2: Sales of tacrolimus ointment in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
The main sales market of this product is currently in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
In 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
In 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
The original research company Leo occupies a leading position in the three major terminals, and there is huge market space for domestically produced replacement of the original research
.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
Table 1: Application status of tacrolimus ointment currently under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, the companies applying for listing under the new classification include Hubei Hengan Fulin Pharmaceuticals and Yangzijiang Pharmaceutical Group.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
Source: CDE official website, Minet database
Medical Network, July 9 News On July 8, Shandong Dyne Marine Biopharmaceuticals and Shandong Liangfu Pharmaceuticals submitted applications for the imitation of tacrolimus ointment in four categories and were accepted
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
Figure 1: The latest product status
Source: CDE official website
Tacrolimus ointment is suitable for the treatment of patients with moderate to severe atopic dermatitis who are not immunocompromised due to potential danger and who are not suitable for traditional therapies or who do not respond adequately to or can not tolerate traditional therapies.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
Figure 2: Sales of tacrolimus ointment in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
The main sales market of this product is currently in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
In 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
In 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
The original research company Leo occupies a leading position in the three major terminals, and there is huge market space for domestically produced replacement of the original research
.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
Table 1: Application status of tacrolimus ointment currently under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, the companies applying for listing under the new classification include Hubei Hengan Fulin Pharmaceuticals and Yangzijiang Pharmaceutical Group.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
Source: CDE official website, Minet database
Medical Network, July 9 News On July 8, Shandong Dyne Marine Biopharmaceuticals and Shandong Liangfu Pharmaceuticals submitted applications for the imitation of tacrolimus ointment in four categories and were accepted
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
.
Tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
Figure 1: The latest product status
Source: CDE official website
Tacrolimus ointment is suitable for the treatment of patients with moderate to severe atopic dermatitis who are not immunocompromised due to potential danger and who are not suitable for traditional therapies or who do not respond adequately to or can not tolerate traditional therapies.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
It can be used for short-term or intermittent use.
Sexual long-term treatment
.
Figure 2: Sales of tacrolimus ointment in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
The main sales market of this product is currently in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
In 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
Hospital hospital hospital pharmacy pharmacy pharmacyIn 2020, affected by the epidemic, the sales growth rate has declined.
Ranked fourth in the TOP list of medicated ointment varieties; in Chinese urban physical pharmacies , sales of this product have soared, exceeding 100 million yuan in 2019, and rising 1% against the trend in 2020.
It is used in dermatological ointments.
Ranked 12th in the TOP list of varieties
.
The original research company Leo occupies a leading position in the three major terminals, and there is huge market space for domestically produced replacement of the original research
.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
Enterprise business enterprise.
At present, there are 7 domestic pharmaceutical companies that have obtained approval for the production of this product.
Among them, Chifeng Wanze Pharmaceutical was approved and reviewed according to the new classification in 2020.
Currently, no company has submitted a supplementary application for consistency evaluation
.
Table 1: Application status of tacrolimus ointment currently under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, the companies applying for listing under the new classification include Hubei Hengan Fulin Pharmaceuticals and Yangzijiang Pharmaceutical Group.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
After the entry of the two pharmaceutical companies in Shandong, the market competition will become more intense.
Who can become the second company to pass the evaluation, we wait for the results
.
Source: CDE official website, Minet database
